In Brief: Baxter
This article was originally published in The Gray Sheet
Baxter: U.S. clinicals of the Edwards MIRA bileaflet mechanical heart valve are scheduled to begin in 1998, pending FDA approval of an investigational device exemption. The device, which received European CE mark approval on Dec. 9, features a new "sewing ring" design as well as technology from Baxter's Starr-Edwards silastic ball valve, and is "particularly suitable for a wide variety of surgical techniques, including...minimally invasive techniques," the company claims. The Edwards MIRA is manufactured by Fiat Group subsidiary Sorin Biomedica and will be marketed worldwide by Baxter under a 1996 agreement...
You may also be interested in...
The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.